SMARCA1 and prostate cancer: The TMB-H and MSI-H ratios corresponding to SWI/SNF-mutant tumors were also significantly higher than those corresponding to the SWI/SNF-non-mutant tumors (TMB-H ratio: 44.3% vs. 10.3%, p  < 0.0001; MSI-H ratio: 16.0% vs. 0.9%, p  < 0.0001), even though the differences were not significant for certain malignancies, such as kidney cancer, pancreatic cancer, prostate cancer, and urothelial cancer.